Rational choice of monotherapy for the treatment of type 2 diabetes mellitus based on the pharmacoeconomical analysis

Авторы

  • Tatyana Ivko Винницкий национальный медицинский университет им. Пирогова ул.Пирогова 56, г. Винница, Украина, 21018, Ukraine
  • Tamara Germanyuk National Pirogov Memorial Medical University Pyrogov str 56, Vinnytsya , Ukraine, 21018, Ukraine

DOI:

https://doi.org/10.15587/2313-8416.2014.32109

Ключевые слова:

diabetes mellitus, retrospective analysis, monotherapy, cost-effectiveness analysis, sensitivity analysis

Аннотация

Research was conducted to scientific justification of rational choice of monotherapy diabetes mellitus (DM) type 2 based on the pharmacoeconomical analysis. It has been found that the unit of efficiency was the cheapest in the scheme of the monotherapy with gliclazide and most expensive – in the scheme of the monotherapy with metformin.

Биографии авторов

Tatyana Ivko, Винницкий национальный медицинский университет им. Пирогова ул.Пирогова 56, г. Винница, Украина, 21018

Ассистент

Кафедра фармации

Tamara Germanyuk, National Pirogov Memorial Medical University Pyrogov str 56, Vinnytsya , Ukraine, 21018

MD, professor of Ukraine, Russia and Kazakhstan

Pharmacy Department

Библиографические ссылки

Dovidnik osnovnih pokaznikiv diyalnosti endokrinologichnoyi sluzhbi Ukrayini za 2011, 2012, 2013.

Nakaz MOZ Ukrayini vid 21.12.2012 N 1118 «Unifikovaniy klinichniy protokol pervinnoyi ta vtorinnoyi (spetsializovanoyi) medichnoyi dopomogi».

Nathan, D. M., Buse, J. B., Davidson, M. B. et al. (2009). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiationand adjustment of therapy. Diabetes Care, 32 (1), 193–203. doi: 10.2337/dc08-2195

Dedov, I. I., Shestakova, M. V., Ametov, A. S. et. al. (2011). Konsensus soveta ekspertov Rossiyskoy assotsiatsii endokrinologov po initsiatsii i intensifikatsii saharosnizhayushchey terapii u bolnyh saharnym diabetom 2 tipa. Normativnye dokumenty. Saharnyy diabet, 4, 7–17

Zherdova, N. M. (2014). Individualniy pidhid do likuvannya hvorih na tsukroviy diabet 2-go tipu. Ukrayinskiy medichniy chasopis, 1 (99), 37–40.

Yagudinа, R. I., Kulikov, A. Yu., Arinina, E. E. (2011). Farmakoekonomika saharnogo diabeta vtorogo tipa. Moscow: OOO «Meditsinskoe informatsionnoe agentstvo», 64–66.

Pravinkumar, I., Тalelem, G. (2012). Adverse effects of metformin in combination with glimepiride and glibenclamide in patients with type 2 diabetes mellitus. Asian Journal of Pharmaceutical and Clinical Research, 5, 108–110.

Yakovleva, L. V., Kirichenko, O. N. (2011). Farmakoepidemiologichne i farmakoekonomicheskiy otsinka likuvannya diabetu. Klinichna endokrinologiya ta endokrinna hirurgiya, 2, 10–20.

Abdulganiyu, G., Fola, T. (2014). Cost-cost analysis of anti-diabetic therapy in a tertiary healthcare. International journal of pharmacy and pharmaceutical sciences, 6, 281–286.

Guidelines for ATC classification and DDD assignment 2013 р.15electronic resource. Available at: www.whocc.no/atc_ddd_index

Register wholesale prices of medicines electronic resource. Available at: www.moz.gov.ua/ua/register_prices_drugs

Загрузки

Опубликован

2014-12-22

Выпуск

Раздел

Фармацевтические науки